ResMed Moves into South Korea

ResMed Moves into South Korea

by | Mar 17, 2019 9:04 pm | Home Health & Hospice

Sleep apnea doesn’t discriminate. The condition occurs everywhere, and that’s where ResMed, Inc. (NYSE: RMD) is going. On March 8, the medical device maker bought HB Healthcare in Seoul, South Korea, for an undisclosed amount. HB provides home medical equipment provider and serves both reimbursed and cash-pay customers to assist with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. The move comes after the Korean government’s July 2018 decision to begin National Health Insurance Service reimbursement for sleep apnea diagnosis and CPAP treatment devices. One in five Korean adults could have sleep apnea, according to a study by Ansan... Read More »
Propeller Health Flies to ResMed

Propeller Health Flies to ResMed

by | Dec 11, 2018 11:45 am | eHealth, Medical Devices

And Propeller Health makes three. Three deals in 2018, that is, for ResMed Inc. (NYSE: RMD), which picked up Propeller for $225 million on December 3. ResMed is a global medical device maker with more than 6 million cloud-connected devices for daily remote patient monitoring for conditions like sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Propeller Health is a digital therapeutics company based in Madison, Wisconsin and backed by Aptar Pharma, Safeguard Scientifics, Social Capital, Hikma, 3M Ventures and SR One. Its products treat COPD patients in Stage 2 and 3 severity levels through connectivity, analytics and companion digital experiences.... Read More »
ResMed Pays Big for MatrixCare

ResMed Pays Big for MatrixCare

by | Nov 9, 2018 2:55 pm | eHealth

It’s a frothy, frothy market in most areas of health care, and the digital health space just got frothier. ResMed Inc. (NYSE: RMD), which makes medical equipment to monitor respiratory disorders, announced it paid $750 million for MatrixCare, a portfolio company of OMERS Private Equity. Right up front, ResMed touted the 25x price/EBITDA multiple, based on MatrixCare’s pro forma net EBITDA of approximately $30 million for calendar year 2018. Pro forma net revenue of $122 million in the same period is approximately 6.2x. The valuation is higher than even the sector’s biggest deal this year, Verscend Technologies’ $4.9 billion take-private deal for Cotiviti Holdings... Read More »